{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:33Z","timestamp":1793398233658,"version":"4.5.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The safety and efficacy of chimeric antigen receptor T-cell therapy is not well described in older patients, a population that has higher frailty and comorbidities. In this multicenter retrospective study, we evaluated clinical outcomes along with frailty and geriatric characteristics such as comorbidities, polypharmacy, falls, neuropathy, organ dysfunction, and performance status in younger (aged &amp;lt;65 years) vs older (aged \u226565 years) patients who received commercial idecabtagene vicleucel (ide-cel). A total of 156 patients (n\u00a0=\u00a075, aged \u226565 years) were infused with ide-cel by data cutoff. In older patients (median age: 69 years; range, 65-83; 66.7% frail; 77.3% did not meet KarMMa eligibility criteria), with a median follow-up duration of 14.2\u00a0months, best overall response rate (ORR) was 86.7%, which was comparable with pivotal KarMMa study results (ORR: 73%). Median progression-free survival and overall survival in older patients were 9.1\u00a0months and 26.5\u00a0months, respectively. Grade \u22653 cytokine-release syndrome and immune effector cell\u2013associated neurotoxicity syndrome were observed in 1% and 4% of older patients, respectively. Compared with younger patients, the older patients had significantly higher prevalence of frailty, geriatric characteristics such as polypharmacy (\u22655 drugs; 97%), \u22654 comorbidities (69%), and organ dysfunction (35%; P\u00a0&amp;lt; .05). The safety and efficacy of ide-cel therapy were similar in younger and older patients. Frailty and geriatric characteristics such as polypharmacy, comorbidities, and organ dysfunction in older patients did not confer an inferior overall outcome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013540","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T21:05:56Z","timestamp":1721768756000},"page":"4679-4688","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience"],"prefix":"10.1182","volume":"8","author":[{"given":"Nilesh M.","family":"Kalariya","sequence":"first","affiliation":[{"name":"1Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A. T.","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"2Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"3Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"4Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Ferreri","sequence":"additional","affiliation":[{"name":"5Atrium Health, Wake Forest University School of Medicine, Levine Cancer Institute, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Doyle","sequence":"additional","affiliation":[{"name":"2Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Castaneda-Puglianini","sequence":"additional","affiliation":[{"name":"2Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"2Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Hovanky","sequence":"additional","affiliation":[{"name":"3Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[{"name":"3Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla O.","family":"Shune","sequence":"additional","affiliation":[{"name":"6The University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"2024091013003384300_bib1","first-page":"423","article-title":"Multiple myeloma in the very elderly patient: challenges and solutions","volume":"11","author":"Willan","year":"2016","journal-title":"CIA"},{"issue":"2","key":"2024091013003384300_bib2","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11899-019-00500-4","article-title":"Challenges and strategies in the management of multiple myeloma in the elderly population","volume":"14","author":"Zanwar","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"2024091013003384300_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity","volume":"125","author":"Rosenberg","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2024091013003384300_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"2024091013003384300_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ejh.13530","article-title":"Survival trends in elderly myeloma patients","volume":"106","author":"Jones","year":"2021","journal-title":"Eur J Haematol"},{"key":"2024091013003384300_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/EDBK_175171","article-title":"Myeloma in elderly patients: when less is more and more is more","volume":"37","author":"Rosko","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"2024091013003384300_bib7","first-page":"e3669","article-title":"Treatment of multiple myeloma in elderly patients: a review of literature and practice guidelines","volume":"10","author":"Manapuram","year":"2018","journal-title":"Cureus"},{"key":"2024091013003384300_bib8","author":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program","year":"2017"},{"issue":"9868","key":"2024091013003384300_bib9","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"2024091013003384300_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024091013003384300_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A\u00a0simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2024091013003384300_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024091013003384300_bib13","unstructured":"National Cancer Institute\n          . Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. US Department of Health and Human Services. 2017. Accessed 22 November 2022. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"8","key":"2024091013003384300_bib14","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024091013003384300_bib15","doi-asserted-by":"crossref","first-page":"612696","DOI":"10.3389\/fmed.2021.612696","article-title":"Approaches and challenges in the management of multiple myeloma in the very old: future treatment prospects","volume":"8","author":"Kaweme","year":"2021","journal-title":"Front Med"},{"issue":"11","key":"2024091013003384300_bib16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024091013003384300_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jtct.2023.03.012","article-title":"Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024091013003384300_bib18","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.jtct.2023.12.239","article-title":"Real world outcomes of older adults and frail patients with relapse\/refractory multiple myeloma receiving idecabtagene vicleucel","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024091013003384300_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11864-000-0056-3","article-title":"Smoldering, asymptomatic stage 1, and indolent myeloma","volume":"1","author":"Greipp","year":"2000","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"2024091013003384300_bib20","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers"},{"issue":"suppl 1","key":"2024091013003384300_bib21","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1182\/blood-2022-166196","article-title":"Real-world analysis of cytopenias after chimeric antigen receptor T-cell therapy: a comparison of BCMA and CD19 based outcomes","volume":"140","author":"Zhuang","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2024091013003384300_bib22","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jgo.2022.07.001","article-title":"Disparities in clinical trial participation among older adults with multiple myeloma in the United States","volume":"13","author":"White","year":"2022","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"1","key":"2024091013003384300_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3322\/caac.21638","article-title":"Older adult participation in cancer clinical trials: a systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2024091013003384300_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2024091013003384300_bib25","first-page":"010414","article-title":"Mapping the global research landscape and knowledge gaps on multimorbidity: a bibliometric study","volume":"7","author":"Xu","year":"2017","journal-title":"J\u00a0Glob Health"},{"key":"2024091013003384300_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/RMHP.S97248","article-title":"Multimorbidity in chronic disease: impact on health care resources and costs","volume":"9","author":"McPhail","year":"2016","journal-title":"Rmhp"},{"issue":"1","key":"2024091013003384300_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1078155219835303","article-title":"Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy","volume":"26","author":"Um\u0131t","year":"2020","journal-title":"J\u00a0Oncol Pharm Pract"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4679\/2241191\/blooda_adv-2024-013540-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/17\/4679\/2241191\/blooda_adv-2024-013540-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T13:01:20Z","timestamp":1725973280000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/17\/4679\/517133\/Clinical-outcomes-after-idecabtagene-vicleucel-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":27,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013540","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]}}}